Articles

Israelis are a people who have learned to do more, with less.

Approaching midyear, what are some observations on the cannabis industry from a global perspective for 2018

The international battle for medical vapes has now begun in earnest. For those who were unaware of the impending skirmish, the details of this showdown at the vape version of the OK Corral are also nuanced.

In Germany, the law now says that all health insurance companies have to pick up the tab for medical cannabis. But there is a procedural and scientific process to establish as the country mainstreams cannabis.

Part II of II: One of the biggest reasons that integration of cannabis is not going smoothly in Germany (besides an outrageous price still driven by supply chain inefficiencies, bureaucracy, and imports). MS is the only on-label condition that more or less automatically gets insurance coverage for cannabis. Everyone else has to rely on their doctor’s ability to persuade insurers to cover a stigmatized, trial-to-mainstreaming drug for conditions that range from ADD to cancer.

Part I of II: It is not news anymore in the United States that the cannabis reform that kicked up the conversation at the state level just four years ago has now gone global. Canada’s recreational market which will begin this summer, nationally, has already demonstrated that what started in the U.S. states (if not Holland before that) is now a world-wide movement if not legit industry.